Gotta wonder why this potency issue wasn’t addressed BEFORE the 2nd BLA application was presented. I can only assuage that the FDA has been playing a ‘cat & mouse’ game with mesoblast…….throughout the process a lot of virtue signalling about the therapy…head nodding…..everything is ‘reasonable….the welcome mat is out….until the moment of truth arrives for actual approval…..then that welcome mat morphs into a trapdoor that propels you into a myriad of dead end delay pathways.
Ann: Mesoblast Type A Meeting with FDA, page-7
-
- There are more pages in this discussion • 568 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.020(1.81%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.14 | $1.08 | $2.936M | 2.651M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 33014 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 92617 | 18 |
View Market Depth
| Last trade - 14.46pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |